OBJECTIVES: To investigate the expression of peroxisome proliferator activator-receptor (PPAR)-alpha, beta, and gamma in human testicular cancer (TC) and normal testicular (NT) tissues, as well as the effects of the PPAR-gamma ligand. Recent studies have demonstrated that PPAR-gamma is expressed in various cancer tissues and its ligand induces growth arrest of these cancer cells through apoptosis. However, the expression of PPARs and the effects of PPAR-gamma ligand in testis have not been examined. METHODS: Tumor specimens were obtained from 72 patients with TC. Specimens were obtained from 20 patients with NT tissue. The expressions were investigated using reverse transcriptase-polymerase chain reaction and immunohistochemical methods. We also investigated the inhibitory effect of the PPAR-gamma ligand on the TC-derived cell line. RESULTS: Immunoreactive PPAR-alpha and beta were significantly apparent in TC tissues. Marked expression of PPAR-alpha and beta was also detected in the NT group. However, very weak or no expression of immunoreactive PPAR-gamma was found in the NT cases. In contrast, we found significant expression of immunoreactive PPAR-gamma in the cancer cells in the TC group. The synthetic PPAR-gamma agonists thiazolidinedione compounds and the endogenous PPAR-gamma ligand, 15-deoxy-Delta-prostaglandin J(2), inhibited the growth of the TC cells. CONCLUSIONS: PPAR-gamma is induced in TC, and the results suggest that PPAR-gamma ligands may mediate potent antiproliferative effects against TC cells through differentiation. Thus, PPAR-gamma may become a new target in the treatment of TC.
OBJECTIVES: To investigate the expression of peroxisome proliferator activator-receptor (PPAR)-alpha, beta, and gamma in humantesticular cancer (TC) and normal testicular (NT) tissues, as well as the effects of the PPAR-gamma ligand. Recent studies have demonstrated that PPAR-gamma is expressed in various cancer tissues and its ligand induces growth arrest of these cancer cells through apoptosis. However, the expression of PPARs and the effects of PPAR-gamma ligand in testis have not been examined. METHODS: Tumor specimens were obtained from 72 patients with TC. Specimens were obtained from 20 patients with NT tissue. The expressions were investigated using reverse transcriptase-polymerase chain reaction and immunohistochemical methods. We also investigated the inhibitory effect of the PPAR-gamma ligand on the TC-derived cell line. RESULTS: Immunoreactive PPAR-alpha and beta were significantly apparent in TC tissues. Marked expression of PPAR-alpha and beta was also detected in the NT group. However, very weak or no expression of immunoreactive PPAR-gamma was found in the NT cases. In contrast, we found significant expression of immunoreactive PPAR-gamma in the cancer cells in the TC group. The synthetic PPAR-gamma agonists thiazolidinedione compounds and the endogenous PPAR-gamma ligand, 15-deoxy-Delta-prostaglandin J(2), inhibited the growth of the TC cells. CONCLUSIONS:PPAR-gamma is induced in TC, and the results suggest that PPAR-gamma ligands may mediate potent antiproliferative effects against TC cells through differentiation. Thus, PPAR-gamma may become a new target in the treatment of TC.
Authors: Markus P Ghadimi; Ping Liu; Tingsheng Peng; Svetlana Bolshakov; Eric D Young; Keila E Torres; Chiara Colombo; Aviad Hoffman; Dominique Broccoli; Jason L Hornick; Alexander J Lazar; Peter Pisters; Raphael E Pollock; Dina Lev Journal: Cancer Date: 2011-05-19 Impact factor: 6.860
Authors: Sharon E Campbell; William L Stone; Steven Lee; Sarah Whaley; Hongsong Yang; Min Qui; Paige Goforth; Devin Sherman; Derek McHaffie; Koyamangalath Krishnan Journal: BMC Cancer Date: 2006-01-17 Impact factor: 4.430
Authors: Raquel Grau; Manuel D Díaz-Muñoz; Cristina Cacheiro-Llaguno; Manuel Fresno; Miguel A Iñiguez Journal: PPAR Res Date: 2008 Impact factor: 4.964